New Nordic fund prone for second investment – pours millions into antiviral spinout
In cooperation with the Danish Growth Fund, the recently launched life science fund Eir Ventures has invested a few million dollars into biotech firm Synklino, which is developing an antiviral medication with an annual revenue outlook of USD 1 billion.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.